EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Genetically engineered macrophages reverse the immunosuppressive tumor microenvironment and improve immunotherapeutic efficacy in TNBC

Ranran Jiang, Liechi Yang, Xin Liu, Yujun Xu, Lulu Han, Yuxin Chen, Ge Gao, Meng Wang, Tong Su, Huizhong Li, Lin Fang, Nan Sun und 3 weitere

Molecular Therapy · 2025-07 · 33 (7) · 3339-3359

DOI: 10.1016/j.ymthe.2025.03.024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2025-07. Verfasst von Ranran Jiang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Nanjing Medical University, 101 Longmian Avenue, Nanjing, Jiangsu 211166, China; Cancer Institute, Xuzhou Medical University,…. Hauptthemen laut MEDLINE: Tumor Microenvironment, Immunotherapy, Macrophages, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Ministry of Science and Technology of the People's Republic of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The main challenges in current immunotherapy for triple-negative breast cancer (TNBC) lie in the immunosuppressive tumor microenvironment (TME). Considering tumor-associated macrophages (TAMs) are the most abundant immune cells in the TME, resetting TAMs is a promising strategy for ameliorating the immunosuppressive TME. Here, we developed genetically engineered macrophages (GEMs) with gene-carrying adenoviruses, to maintain the M1-like phenotype and directly deliver the immune regulators interleukin-12 and CXCL9 into local tumors, thereby reversing the immunosuppressive TME. In tumor-bearing mice, GEMs demonstrated targeted enrichment in tumors and successfully reprogramed TAMs to M1-like macrophages. Moreover, GEMs significantly enhanced the accumulation, proliferation, and activation of CD8+ T cells, mature dendritic cells, and natural killer cells within tumors, while diminishing M2-like macrophages, immunosuppressive myeloid-derived suppressor cells, and regulatory T cells. This treatment efficiently suppressed tumor growth. In addition, combination therapy with GEMs and anti-programmed cell death protein 1 further improved interferon-γ+CD8+ T cell percentages and tumor inhibition efficacy in an orthotopic murine TNBC model. Therefore, this study provides a novel strategy for reversing the immunosuppressive TME and improving immunotherapeutic efficacy through live macrophage-mediated gene delivery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentImmunotherapyMacrophagesTriple Negative Breast NeoplasmsTumor-Associated MacrophagesAnimalsMiceFemaleHumansCell Line, TumorGenetic EngineeringDisease Models, AnimalInterleukin-12Chemokine CXCL9Genetic VectorsCD8-Positive T-LymphocytesAdenoviridaeGenetic Therapy

Stichwörter der Autor:innen

CXCL9GEMsIL-12TAMsTMEgenetically engineered macrophageslive macrophage-mediated gene deliverytumor immune microenvironmenttumor-associated macrophages

Substanzen

Interleukin-12Chemokine CXCL9

Autor:innen und Institutionen

  • Department of Oncology, Nanjing Medical University, 101 Longmian Avenue, Nanjing, Jiangsu 211166, China; Cancer Institute, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, Jiangsu 221004, China; Center of Clinical…
  • Department of Neurosurgery, The Affiliated Hospital of Xuzhou Medical University, 99 Huaihai Road, Xuzhou, Jiangsu 221002, China.
  • Cancer Institute, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, Jiangsu 221004, China; Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, 99 Huaihai Road, Xuzhou, Jiangsu 221002,…
  • Department of Oncology, Nanjing Medical University, 101 Longmian Avenue, Nanjing, Jiangsu 211166, China; Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, 99 Huaihai Road, Xuzhou, Jiangs…

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Ministry of Science and Technology of the People's Republic of China
  • Jiangsu Provincial Key Research and Development Program
  • Jiangsu Provincial Department of Education

Zitieren

APA

Jiang, R., Yang, L., Liu, X., Xu, Y., Han, L., Chen, Y., Gao, G., Wang, M., Su, T., Li, H., Fang, L., Sun, N., Du, H., Zheng, J., & Wang, G. (2025). Genetically engineered macrophages reverse the immunosuppressive tumor microenvironment and improve immunotherapeutic efficacy in TNBC. Molecular Therapy, 33(7), 3339-3359. https://doi.org/10.1016/j.ymthe.2025.03.024

Vancouver

Jiang R, Yang L, Liu X, Xu Y, Han L, Chen Y, et al. Genetically engineered macrophages reverse the immunosuppressive tumor microenvironment and improve immunotherapeutic efficacy in TNBC. Molecular Therapy. 2025;33(7):3339-3359. doi:10.1016/j.ymthe.2025.03.024

BibTeX
@article{Jiang2025,
  author = {Jiang, Ranran and Yang, Liechi and Liu, Xin and Xu, Yujun and Han, Lulu and Chen, Yuxin and Gao, Ge and Wang, Meng and Su, Tong and Li, Huizhong and Fang, Lin and Sun, Nan and Du, Hongwei and Zheng, Junnian and Wang, Gang},
  title = {Genetically engineered macrophages reverse the immunosuppressive tumor microenvironment and improve immunotherapeutic efficacy in TNBC},
  journal = {Molecular Therapy},
  year = {2025},
  volume = {33},
  number = {7},
  pages = {3339--3359},
  doi = {10.1016/j.ymthe.2025.03.024}
}
Kostenlos starten →